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Abstract
Background: MicroRNAs (miRNAs) have been documented as playing important roles in cancer development. In
this study, we investigated to clarify the clinicopathological significance and prognostic value of miR-124 in breast
cancer.
Methods: Quantitative Real-time PCR method was used to assess the expression levels of miR-124 in breast cancer
patients and the association of miR-124 expression levels with the clinicopathological characteristics in breast cancer
patients. Survival and Multivariate Cox proportional hazards model analysis was used to evaluate whether the miR-124
expression level and various clinicopathological characteristics were independent prognostic marker for breast cancer
patients.
Results: We found that the lower expression of miR-124 in breast cancer specimens compared with corresponding
adjacent normal breast tissues P < 0.05. Results showed that decreased expression of miR-124 was significantly related to
advanced clinical stage (stage III and IV) (P = 0.021) and positive lymph node-metastasis (P = 0.011). Patients with low
expression of miR-124 had significantly shorter overall survival (70.2 %) than patients who had cancers with high miR-124
expression (29.8), (logrank test P = 0.021). Moreover, Multivariate Cox proportional hazards model analysis indicated that
lowr miR-124 expression was found to be independently linked to poor survival of patients with breast cancer and other
factors were not significantly associated with survival of patients.
Conclusion: Our data suggested that decreased expression of miR-124 has prognostic value in breast cancer and may
serve as a prognostic marker for breast cancer, and also downregulation of miR-124 was inversely associated with the
lymph node metastasis in breast cancer.
Background
Breast cancer is cause of cancer related mortality among
women worldwide [1, 2]. Results of molecular research in
breast cancer patients may be useful in order to improve
the management of patients and also it can help to identify
the therapeutic effect of these mechanisms. MicroRNAs
(miRNAs) are small, non-coding RNA molecules that are
involved in post-transcriptional gene regulation,and
functions in RNA silencing and post-transcriptional
regulation of gene expression [3–6]. As matter of fact,
these small RNAs regulate gene expression by directing
their target mRNAs for degradation or translational repres-
sion [7]. Thereby, controlling a wide range of biological
functions such as cellular proliferation, differentiation, and
apoptosis. With the advent of miRNA expression profiles,
significant efforts have been done to evaluate the correl-
ation of miRNAs expression with tumor prognosis [8, 9]. It
is worth noting that alteration in microRNA expression
may play a critical role in tumorigenesis and cancer pro-
gression [10]. These differences in expression of miRNAs
can be useful (as biomarkers) for breast cancer progression
and clinical course, as well as may play a critical role in the
transformation process [10–12].
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Previous studies have suggested that miR-124 was epi-
genetically silenced in various types of cancers [13, 14].
These studies highlighted an important role of miR-124 in
the regulation of invasion and metastasis in breast cancer
cells, and suggest a potential application of miR-124 in
prognosis prediction and cancer treatment. Li et al. [3]
demonstrated that miR-124 was downregulated in breast
cancer and might act as a tumor suppressor in breast can-
cer via the regulation of FLOT1.
In the present study, we investigated the role of miR-124
in breast cancer and the clinicopathological significance
and prognostic value of miR-124.
Methods
Patients
A total of 100 breast cancer tissues and adjacent normal
tissues were evaluated after taking the informed con-
sents in current study. All patients underwent breast
surgical resection at Tehran between March 2010 and
March 2014. None of these patients had received radio-
therapy or chemotherapy prior to surgery. The carcin-
omas and the adjacent normal tissues were snap frozen
in liquid and then stored at −80 °C until use. All the
specimens were diagnosed by pathologists. None of the
patients recruited in current study had undergone pre-
operative chemotherapy or radiotherapy. Patients’ clinical
information stored in a database and was summarized in
Table 1.
Quantitative real-time PCR
Total RNA and enrichment of small RNA was isolated
from fresh samples using the miRVana™ microRNA. Isola-
tion Kit (Applied Biosystems/Ambion, Austin, TX,. USA)
according to the manufacturer’s protocol and stored
at −80 °C until use. Total RNA from fresh cultured cells
was extracted with TRIzol reagent (Invitrogen, Carlsbad,
California, USA). Real-time.
Real-time PCR was carried out using an Express SYBR®
GreenER qPCRs supermix Universal kit (Invitrogen) on a
Rotor-gene 6000 system (Qiagen, Valencia, CA, USA).
USA). The relative amount of miR-124was normalized
against U6 RNA. In current study, we calculated a ΔCt
(target-reference) that is equal to the difference be-
tween threshold cycles for miR-124 (target) and those
for U6 RNA.
The fold-change between cancer tissues and normal
breast tissue control for miR-124 was calculated by the
2ΔΔCt method, in which ΔΔCt = ΔCt (target-reference in
tumor samples) - ΔCt (target-reference in normal sam-
ples). The relative expression levels of miRNAs in cancer
compared to their non-tumorous controls were calculated
using the method of 2-ΔΔCt. The primers for miR-124
were used as follows: forward: 5′-GATACTCATAAGGCA
CGCGG-3′ and reverse: 5′-GTGCAGGGTCCGAGGT-3′.
Statistical analysis
The software, SPSS Version 16.0 for Windows (SPSS Inc.,
Chicago, IL, USA), was used for analysis. Differences in
miR-124 expression between the tumor and normal tis-
sues were analyzed using the Student’s t-test. Moreover,
the chi-square test and Fisher’s exact test were used to
evaluate the relationships between miR-124 expression
level and the clinicopathological characteristics. Differ-
ences were considered significant when P < 0.05. Survival
curves were plotted by the Kaplan-Meier method and
compared by the log-rank test. The survival data were
evaluated by multivariate Cox regression analyses.
Ethical approval
All parts of the study were approved by the Institutional
Ethical Committee of the First Affiliated Hospital of
Tehran Province, and informed consent according to the
Declaration of Helsinki was obtained from all partici-
pants or their families/surrogates.
Results
To compare the miR-124 expression levels in breast cancer
specimens and normal breast tissues, real-time analysis per-
formed. The results have showed that lower expression of
miR-124 in breast cancer specimens when compared with
corresponding adjacent normal breast tissues P < 0.05.
Table 1 Relationship between miR-124 expression and
clinicopathological characteristics of patients
Variables Number of cases miR-124expression P value
Low High
Age (years)
<60 58 22 36 0.231
≥60 42 25 17
TNM stage
I + II 68 24 44 0.021
III 32 23 9
Lymph node metastasis
Yes 34 26 8 0.011
No 66 18 48
ER status
Positive 40 24 16 0.41
Negative 60 19 21
PR status
Positive 55 25 30 0.13
Negative 45 26 19
HER2 status
Positive 42 16 26 0.12
Negative 58 34 24









According to the median level of miR-124, breast can-
cer patients were classified in to low and high expression
groups. 53 cases were assigned to the low miR-14-8b ex-
pression group, while 47 cases were classified to the high
expression group.
Association of miR-124 expression levels with the
clinicopathological outcome
Association of miR-124 expression levels with the clini-
copathological characteristics patients with breast cancer
are summarized in Table 1. Results showed that decreased
expression of miR-124 was significantly related to advanced
clinical stage (stage III and IV) (P = 0.021) and positive
lymph node-metastasis (P = 0.011).
However, miR-124 expression was not found to be as-
sociated with other clinicopathological characteristics in-
cluding, age (P = 0.231), ER status (P = 0.41), PR status
(P = 0.13), and HER2 status (P = 0.12).
Survival analysis in two groups based on their miR-148b
expression level
Kaplan-Meier survival analysis and log-rank test demon-
strated that patients with low expression of miR-124 had
significantly shorter overall survival (70.2 %) than patients
who had cancers with high miR-124 expression (29.8),
(logrank test P = 0.021).
Multivariate Cox proportional hazards model analysis
Multivariate Cox proportional hazards model analysis
was used to evaluate whether the miR-124 expression
level and various clinicopathological characteristics were
independent prognostic marker for breast cancer patient.
The result indicated that lower expression level of miR-
124 was independently linked to poor survival of patients
with breast cancer and other factors were not significantly
associated with survival of patients (Table 2).
Discussion
Results of molecular research may improve the manage-
ment of patients, as well as it is essential to identify power-
ful prognostic indicator for breast cancer.
It was found that the deregulated miRNAs was corre-
lated with substantial cell physiological and pathological
processes and is ultimately involved in tumorigenesis and
the tumor progression of many different human cancers.
For instance, ectopical expression of miR-148b inhibits the
invasion, survival to anoikis, extravasation in breast cancer,
and lung metastasis formation of breast cancer cells [15].
In this study, we investigated the role of miR-124 in breast
cancer and the clinicopathological significance and prog-
nostic value of miR-124 in breast cancer. In current study,
MiR-124 downregulation was significantly related to ad-
vanced clinical stage (stage III and IV) and positive lymph
node-metastasis in breast cancer patients. Furthermore, the
results showed that lower expression of miR-124 in breast
cancer specimens when compared with corresponding ad-
jacent normal breast tissues. These results indicated that
miR-124 is downregulated in breast cancer, and decreased
expression of miR-124 may be responsible for the progres-
sion and metastasis of breast cancer. The miR-124 has been
reported that might be involved in epigenetic regulation of
various tumors, including breast cancer [16, 17]. According
to the recent studies, down regulated miR-124 can con-
tribute to lymph node-metastasis and tumor progression
in patients with breast cancer [13, 18] and in other cancers
patients [14, 17, 19]. Previous studies have suggested that
miR-124 was epigenetically silenced in various types of
cancers [13, 17]. These studies highlighted an important
role of miR-124 in the regulation of invasion and me-
tastasis in breast cancer cells, and suggest a potential
application of miR-124 in prognosis prediction and cancer
treatment. Li et al., [3] demonstrated that miR-124 might
be a tumor suppressor in breast cancer via the regulation
of FLOT1. Luciferase assays confirmed that miR- FLOT1
was identified as a direct and functional target of miR-124
that bind to the 3′ untranslated region of FLOT1 and sup-
press translation. They identified that the FLOT1 gene is
as a novel direct target of miR-124, and ectopic expression
of miR-124 significantly inhibited FLOT1 [3]. Han et al.
[13] found that miR-124 was downregulated in breast can-
cer and the ectopic expression of miR-124could suppress
the invasion and metastatic ability, probably by directly
targeting the CD151. It is worth noting that these results
indicated an important role for miR-124 in the prolifera-
tion and metastasis of different cancers [13].
Kaplan-Meier survival analysis and log-rank test dem-
onstrated that patients with low expression of miR-124
had significantly shorter overall survival than patients
who had cancers with high miR-124 expression. Further-
more, multivariate Cox proportional hazards model analysis
indicated that low miR-124 expression was independently
linked to poor survival of patients with breast cancer and
other factors were not significantly associated with survival
of patients. Zhang et al. [20] have shown that decreased ex-
pression of miR-148b was linked to poor overall survival of
Table 2 Multivariate analyses of clinicopathological
characteristics by Cox regression model
Variable Hazard ratio 95 % CI P-value
Age 1.432 0.861–3.611 0.614
TNM stage 2.021 1.455–9.110 0.011
Lymph node metastasis 2.327 0.952–6.656 0.021
ER status 1.012 0.822–2.521 0.423
PR status 0.871 0.265–2.225 0.551
HER2 status 0.752 0.412–2.043 0.563
miR-124 level 3.753 1.623–10.421 0.021









patients with hepatocellular carcinoma, indicating the po-
tential role of miR-148b as a prognostic marker in clinical
practice. Furthermore, Zheng et al. showed that miR-124
levels were frequently reduced in hepatocellular carcinoma,
and this expression level was significantly associated
with the patients’ clinical stages and prognoses, as well
as, regulated the invasion and migration of hepatocellular
carcinoma [14]. In addition, Lv et al., Liang et al. and Han
et al. also reported that miR-124 can suppress breast can-
cer growth and metastasis [13, 18, 21].
Conclusions
In summary, our data suggest that decreased expression
of miR-124 has prognostic value in breast cancer and may
serve as a prognostic marker for breast cancer, as well as
our study indicates that miR-124 is downregulated and is
inversely associated with the lymph node metastasis in
breast cancer.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AAKH and AS conceived the study and searched the literature and drafted the
manuscript. MS and EY contributed to data analysis and interpretation of the
data and helped to draft the manuscript; MG conceived of the study, and
participated in its design and coordination and wrote the manuscript. All
authors read and approved the final manuscript. All the authors participated in
the discussion, provided conceptual input, have read and approved the final
manuscript.
Acknowledgements
We wish to thank Dr. Heydari for attentive editing of our English manuscript.
This work was no fund.
Author details
1Department of Surgery, Cancer and Reconstructive Surgeon, Cancer
Institute, School of Medicine, Tehran University of Medical Sciences, Tehran,
Iran. 2Department of Gynecology, Khanevadeh Hospital, AJA University of
Medical Sciences, Tehran, Iran. 3Department of Molecular Biology,
Baqiyatallah University of Medical Sciences, Tehran, Iran. 4Department of
Radiology, Medical Imaging Center, Tehran University of Medical Sciences,
Tehran, Iran.
Received: 3 June 2015 Accepted: 28 August 2015
References
1. Kim Y, Yoo KY, Goodman MT. Differences in incidence, mortality and
survival of breast cancer by regions and countries in Asia and contributing
factors. Asian Pac J Cancer Prev. 2015;16(7):2857–70.
2. Kim JL, Cho KH, Park EC, Cho WH. A single measure of cancer burden
combining incidence with mortality rates for worldwide application. Asian
Pac J Cancer Prev. 2014;15(1):433–9.
3. Li L, Luo J, Wang B, Wang D, Xie X, Yuan L, et al. Microrna-124 targets
flotillin-1 to regulate proliferation and migration in breast cancer. Mol
Cancer. 2013;12:163.
4. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–5.
5. Khoshnaw SM, Green AR, Powe DG, Ellis IO. MicroRNA involvement in the
pathogenesis and management of breast cancer. J Clin Pathol.
2009;62(5):422–8.
6. Fan M, Krutilina R, Sun J, Sethuraman A, Yang CH, Wu ZH. Comprehensive
analysis of microRNA (miRNA) targets in breast cancer cells. J Biol Chem.
2013;288(38):27480–93.
7. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell.
2009;136(2):215–33.
8. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev
Cancer. 2006;6(11):857–66.
9. Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res.
2005;65(9):3509–12.
10. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer.
Nat Rev Cancer. 2006;6(4):259–69.
11. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ.
MicroRNA expression profiling of human breast cancer identifies new
markers of tumor subtype. Genome Biol. 2007;8(10):R214.
12. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S. MicroRNA
gene expression deregulation in human breast cancer. Cancer Res.
2005;65(16):7065–70.
13. Han ZB, Yang Z, Chi Y, Zhang L, Wang Y, Ji Y. MicroRNA-124 suppresses
breast cancer cell growth and motility by targeting CD151. Cell Physiol
Biochem. 2013;31(6):823–32.
14. Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP. The putative tumour
suppressor microRNA-124 modulates hepatocellular carcinoma cell
aggressiveness by repressing ROCK2 and EZH2. Gut. 2012;61(2):278–89.
15. Cimino D, De Pittà C, Orso F, Zampini M, Casara S, Penna E, et al. miR148b
is a major coordinator of breast cancer progression in a relapse-associated
microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1.
FASEB J. 2013;27(3):1223–35.
16. Wang P, Chen L, Zhang J, Chen H, Fan J, Wang K. Methylation-mediated
silencing of the miR-124 genes facilitates pancreatic cancer progression and
metastasis by targeting Rac1. Oncogene. 2014;33(4):514–24.
17. Wilting SM, van Boerdonk RA, Henken FE, Meijer CJ, Diosdado B, Meijer
GA. Methylation-mediated silencing and tumour suppressive function of
hsa-miR-124 in cervical cancer. Mol Cancer. 2010;9:167.
18. Liang YJ, Wang QY, Zhou CX, Yin QQ, He M, Yu XT. MiR-124 targets Slug to
regulate epithelial-mesenchymal transition and metastasis of breast cancer.
Carcinogenesis. 2013;34(3):713–22.
19. Pierson J, Hostager B, Fan R, Vibhakar R. Regulation of cyclin dependent
kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol. 2008;90:1–7.
20. Zhang Z, Zheng W, Hai J. MicroRNA-148b expression is decreased in
hepatocellular carcinoma and associated with prognosis. Med Oncol.
2014;31:984.
21. Lv XB, Jiao Y, Qing Y, Hu H, Cui X, Lin T, et al. miR-124 suppresses multiple
steps of breast cancer metastasis by targeting a cohort of pro-metastatic
genes in vitro. Chin J Cancer. 2011;30:821–30.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Arabkheradmand et al. Diagnostic Pathology  (2015) 10:178 Page 4 of 4
